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Objective Elevated circulating levels of pro-inflammatory biomarkers are associated with adverse health 
effects, but the extent to which enhanced low-grade inflammation influences remaining life expectancy 
(LE) is uncertain. GlycA is a novel pro-inflammatory marker. We determined effects of GlycA and high 
sensitivity C-reactive protein (hsCRP) on LE.  
Methods GlycA and hsCRP were determined in 5,526 subjects. LE was compared in the upper quartile of 
both GlycA and hsCRP vs. the respective lower three quartiles combined, adjusted for LE of individuals in 
the Dutch general population of the same birth cohort and sex.  
Results Median follow up was 8.5 years [interquartile range 7.9-9.0], during which 348 (6.3%) subjects 
had deceased. LE at the end of follow up was lower in the highest vs. the lower three quartiles of GlycA 
(P<0.001) and hsCRP (P<0.001). Both men as well as women in the highest GlycA quartile had reduced LE 
vs. the lowest three quartiles combined (P<0.001 and P=0.02). For hsCRP, this was only observed in men 
(P<0.001) but not in women (P=0.67).  
Conclusions This population-based cohort study demonstrates that higher plasma levels of GlycA were 
associated with reduced LE in men and women. With regard to hsCRP this only applied to men. 
 





Glycosylation is one the most common post-translational modifications of proteins and is influenced 
by many biological processes, including inflammation [1]. GlycA is a novel nuclear magnetic resonance 
(NMR) spectroscopy measured marker of inflammation, which identifies N-acetyl glycan groups on 
enzymatically glycosylated acute phase proteins (primarily α1-acid glycoprotein, haptoglobin, α1-
antitrypsin, α1-antichymotrypsin and transferrin) [2,3]. GlycA concentrations are robustly correlated with 
those of well described inflammatory biomarkers such as high sensitivity C-reactive protein (hsCRP) [2,4].  
Several studies have shown that GlycA is positively correlated with cardiometabolic risk factors such 
as elevated body mass index (BMI) [5], insulin resistance [6] and components of the metabolic syndrome 
[7]. Furthermore, GlycA is higher in patients with chronic inflammatory conditions [8]. Elevated levels 
were found to be associated with incident type 2 diabetes mellitus (T2DM) and cardiovascular disease 
(CVD) in several large prospective studies [9-12]. Notably, all of these associations were independent of 
traditional risk factors.  
Besides being a marker of chronic inflammatory diseases, GlycA is also associated with all-cause and 
cause specific mortality, independently of established risk factors [13-15]. The study of Lawler et al. 
showed that cardiovascular disease (CVD), colorectal and lung cancer mortality were all significantly 
associated with elevated levels of GlycA among initially healthy subjects [15]. Another study showed that 
higher GlycA levels were associated with increased risk of incident colorectal cancer and colorectal 
cancer mortality, but not with breast cancer or mortality from other cancers [14].  
It is evident that elevated levels of GlycA are related to adverse health effects. Notably however, it is 
uncertain how this influences remaining life expectancy, an increasingly used approach to determine the 
overall effect of a certain condition on survival [16-18]. We initiated the present study to determine 
differences in life expectancy in men and women of the Prevention of Renal and Vascular End Stage 
Disease (PREVEND) cohort with higher vs. lower levels of GlycA and hsCRP. Our method interrogates 
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mortality against life expectancy as the time base. As the individual life expectancies at the time of 
sampling were different, we used left-censoring as well as right-censoring in the calculations of subjects 




2. Material and methods 
2.1 Study design and population 
This study was part of the PREVEND study, a large-scale, observational, general population cohort 
study bases in the Netherlands. The study began in 1997. Details of the study design and recruitment 
have been described in previous reports [19,20]. In brief, 40,856 individuals (47.8%) completed a 
questionnaire on demographics, history of cardiovascular and metabolic outcomes, medication use, 
and pregnancy before their first visit and collected an early morning urine sample in a vial to 
measure urinary albumin concentration. Those who were unable or unwilling to participate, 
individuals using insulin, and pregnant women were excluded. The baseline PREVEND participants 
were recruited from a total of 6,000 individuals with a urinary albumin concentration of 10 mg/L or 
greater and a random control sample of individuals with a urinary albumin concentration of <10 
mg/L (n = 2592). In total, 8,592 individuals constitute the PREVEND cohort and completed an 
extensive examination between 1997 and 1998. The second screening took place from 2001 through 
2003 (n=6,894), which was the starting point of the present evaluation. We excluded 1,368 
individuals with missing data on GlycA and/or hsCRP, leaving 5,526 subjects available for the 
analyses (Fig 1). 
The PREVEND study was approved by the local medical ethics committee of the University 




Figure 1 flowchart of the study. 
 
2.2 Measurements and laboratory analysis 
BMI was calculated as weight (kg) divided by height squared (m2). Smoking status was defined as 
self-reported never smoker, former smoker, or current smoker (<6, 6–20, or >20 cigarettes/day) and 
alcohol intake as no/rarely, 1 to 4 drinks/month, 2 to 7 drinks/week, 1 to 3 drinks/day, and 3 or more 
drinks/day. Blood pressure was measured with an automatic Dinamap XL Model 9300 series device 
(Johnson-Johnson Medical, Tampa, FL, USA). Hypertension was defined as systolic blood pressure of 
≥ 140 mm Hg, a diastolic blood pressure of ≥ 90 mm Hg, or both or the use of antihypertensive 
agents. Type 2 diabetes mellitus (T2DM) was defined as a fasting serum glucose level ≥ 7.0 mmol/L, a 
7 
 
non-fasting plasma glucose level ≥ 11.1 mmol/L, self-report of a physician diagnosis or the use of 
glucose lowering drugs, retrieved from a central pharmacy registry. Estimated glomerular filtration 
rate (eGFR) was calculated using the combined creatinine cystatin C-based Chronic Kidney Disease 
Epidemiology Collaboration equation from 2012 [21]. 
Fasting blood samples were provided and stored at -80 °C. NMR spectra were collected from 
EDTA plasma samples using the Vantera® Clinical Analyzer. The GlycA NMR signal is derived from the 
N-acetyl methyl protons of N-acetylated carbohydrate side chains of serum glycoproteins 
(predominantly, α1-acid glycoprotein, haptoglobin, α1-antitrypsin, α1-antichymotrypsin and 
transferrin) [2] . The GlycA NMR signal is centered at 2.00 ± 0.01 ppm in the NMR spectra of plasma, 
and only N-acetylglucosamine with specific glycosidic linkage, namely, β (1>2) or β (1>6) with a 
preceding mannose residue, contribute to the GlycA signal [2].  
hsCRP was measured by nephelometry with a threshold of 0.18 mg/L (BNII, Dade Behring). 
Plasma glucose was measured as described [6]. Serum total cholesterol was assayed on an automatic 
analyser type MEGA (Merck, Darmstadt, Germany) using the CHOD-PAP-method. Triglycerides (TG) 
and high density lipoprotein cholesterol (HDL-C) were measured on a Beckman Coulter AU Analyzer. 
The intra-assay and inter-assay coefficients of variation for hsCRP and GlycA are 3% and 4.5%, 
and 2% and 3%, respectively. 
 
2.3 Statistical analysis 
Baseline characteristics are presented according to sex-specific GlycA and hsCRP quartiles. 
Continuous data are presented as mean with SD or as median with interquartile range (IQR) in case 
of skewed distribution. Categorical data are presented as numbers with percentages. Pearson 
correlation coefficients were calculated between GlycA and logarithmically transformed hsCRP. Life 
expectancy was calculated as follows. The median residual life time (EXP) was derived from gender 
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specific mortality reports provided by the Dutch Central Office of Statistics (CBS) 
(http://www.CBS.nl). The starting point was the date of blood collection of the individuals at the 
second screening round. . For any person this date was substituted by the median life expectancy of 
individuals in the general population with the same age, gender and year of birth. This 
standardization of survival time enables us to compare mortality at the same life expectancy, 
thereby omitting influence of other risk factors due to age. Because individual life expectancies at 
start of follow-up were different, we had to use left-censoring (apart from right censoring) in the 
calculation of number of persons at risk for Kaplan-Meier curves and log-rank statistics. The time 
base used in the graphs is negative life expectancy (-EXP). Differences were tested using the log-rank 
test with left and right censoring. Results were calculated for the whole group and for men and 
women separately. Life expectancy was compared in the upper quartiles of GlycA and hsCRP vs. the 
lower three quartiles combined. This cut-off was chosen prior to the analyses to be able to evaluate 
the effect of higher GlycA and hsCRP. Two-sided P-values <0.05 were considered statistically 
significant. Analyses were performed using SPSS statistics for Windows, Version 23.0 (Armonk, NY: 
IBM Corp) and Microsoft Excel 2010 for Windows.   
 
3 Results 
Baseline characteristics of the 5,526 subjects according to sex specific quartiles of GlycA are 
presented in Table 1. The mean age of the subjects at start of the study was 53.6±12.1 years. 324 
(5.9%) of the subjects had T2DM and 349 (6.3%) had a history of CVD. Subjects in the highest quartile 
of GlycA were older. Levels of total cholesterol, triglycerides and UAE were higher, whereas HDL 
cholesterol and eGFR were lower in subjects in the highest quartile vs. subjects in the lowest 
quartile. Hypertension, T2DM and a history of CVD were more prevalent among subjects in the 
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highest quartile. Baseline characteristics according to sex specific quartiles of hsCRP were 




 Table 1. Characteristics of the 5,526 subjects of the Prevention of Renal and Vascular End-Stage Disease 
(PREVEND) study according to sex-stratified quartiles of GlycA 
 Q1 Q2 Q3 Q4 P for 
trend 
Number of subjects 1387 1386 1373 1380  
GlycA, µmol/L      
   Men <305 ≥305 ≥339 ≥382  
   Women <314 ≥314 ≥353 ≥394  
Age 49.1±10.8 53.2±12.0 55.4±12.2 56.8±12.1 <0.001 
Sex, n (%)     0.97 
   Men 655 (47.2) 668 (48.2) 653 (47.6) 657 (47.6)  
   Women 732 (52.8) 718 (51.8) 720 (52.4) 723 (52.4)  
BMI, kg/m
2 
24.7±3.4 26.2±3.7 27.3±4.2 28.3±4.9 <0.001 
Smoking status, n (%)     <0.001 
   Non smoker 541 (39.5) 437 (31.9) 335 (24.7) 311 (22.8)  
   Former smoker 588 (42.9) 611 (44.6) 610 (45.0) 539 (39.5)  
   Current smoker 242 (17.7) 322 (23.5) 412 (30.4) 513 (37.6)  
Alcohol consumption      0.22 
   <10 g/d 1010 (73.4) 990 (72.1) 1004 (73.7) 1033 (75.6)  
   ≥10 g/d 366 (26.6) 383 (27.9) 358 (26.3) 333 (24.4)  
Hypertension, n (%) 229 (16.5) 417 (30.1) 548 (39.9) 652 (47.2) <0.001 
Lipid lowering drug use, n (%) 59 (4.3) 111 (8.0) 172 (12.5) 227 (16.4) <0.001 
History of CVD, n (%) 35 (2.5) 81 (5.8) 98 (7.1) 135 (9.8) <0.001 
History of cancer, n (%) 82 (5.9) 80 (5.8) 87 (6.3) 89 (6.4) 0.86 
T2DM, n (%) 24 (1.7) 51 (3.7) 105 (7.6) 144 (10.4) <0.001 
Family history of CVD, n (%) 623 (44.9) 677 (48.8) 701 (51.1) 713 (51.7) 0.001 
Blood pressure lowering drug use, n 
(%) 
135 (9.7) 264 (19.0) 372 (27.1) 459 (33.3) <0.001 
Glucose lowering drug use, n (%) 8 (0.6) 28 (2.0) 59 (4.3) 80 (5.8) <0.001 
SBP, mm Hg 119.0±15.7 124.5±18.2 128.5±19.7 131.3±19.6 <0.001 
DBP, mm Hg 70.4±8.7 72.6±8.8 74.0±8.9 74.7±8.9 <0.001 
Total cholesterol, mmol/L 5.16±1.00 5.40±1.00 5.52±1.05 5.64±1.12 <0.001 
HDL cholesterol, mmol/L 1.34±0.32 1.28±0.30 1.23±0.31 1.20±0.30 <0.001 





























Data are numbers (percentages), means (SD) or medians [interquartile range (IQR)]. P-values were 
calculated by linear regression analysis or χ2 analysis. Triglycerides and UAE were logarithmically 
transformed for analysis. Data with regard to smoking and alcohol consumption were missing in 
65(1.2%) and 49 (0.9%) of the subjects, respectively. Abbreviations: BMI: Abbreviations: BMI, body mass 
index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFRcrea-cysC, estimated glomerular 
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filtration rate based on creatinine-cystatin C equation; HDL, high density lipoproteins; SBP, systolic blood 




Table 2. Characteristics of the 5,526 subjects of the Prevention of Renal and Vascular End-Stage Disease 
(PREVEND) study according to sex-stratified quartiles of hsCRP 
 Q1 Q2 Q3 Q4 P-value 
Number of subjects 1387 1386 1373 1380  
hsCRP, mg/L      
   Men <0.62 ≥0.62 ≥1.31 ≥2.82  
   Women <0.64 ≥0.64 ≥1.43 ≥3.33  
Age 49.1±10.8 53.2±12.0 55.4±12.2 56.8±12.1 <0.001 
Sex, n (%)      
   men 682 683 682 683  
   women 744 745 744 745  
BMI, kg/m
2 
24.2±3.1 26.2±3.5 27.5±4.0 28.6±5.0 <0.001 
Smoking status, n (%)     <0.001 
   Non smoker 521 (37.8) 425 (31.2) 355 (26.1) 323 (23.8)  
   Former smoker 535 (38.8) 611 (44.8) 625 (45.9) 577 (42.6)  
   Current smoker 323 (23.4) 328 (24.0) 382 (28.0) 456 33.6(  
Alcohol consumption      0.23 
   <10 g/d 1004 (72.5) 998 (73.0) 1004 (73.6) 1031 (75.8)  
   ≥10 g/d 381 (27.5) 369 (27.0) 360 (26.4) 330 (24.2)  
Hypertension, n (%) 255 (18.2) 391 (28.4) 541 (39.4) 659 (47.9) <0.001 
Lipid lowering drug use, n (%) 93 (6.7) 125 (9.1) 175 (12.7) 176 (12.8) <0.001 
History of CVD, n (%) 48 (3.4) 68 (4.9) 88 (6.4) 145 (10.5) <0.001 
History of cancer, n (%) 86 (6.2) 79 (5.7) 93 (6.8) 80 (5.8) 0.66 
T2DM, n (%) 34 (2.4) 51(3.7) 95 (6.9) 144 (10.5) <0.001 
Family history of CVD, n (%) 667 (47.7) 683 (49.5) 680 (49.5) 684 (49.7) 0.68 
Blood pressure lowering drug 
use, n (%) 
148 (10.6) 237 (17.2) 373 (27.1) 472 (34.3) <0.001 
Glucose lowering drug use, n (%) 16 (1.1) 30 (2.2) 53 (3.9) 76 (5.5) <0.001 
SBP, mm Hg 119±15 125±18 129±19 131±21 <0.001 
DBP, mm Hg 70±9 73±9 74±9 75±9 <0.001 
Total cholesterol, mmol/L 5.18±1.00 5.45±1.04 5.60±1.09 5.50±1.05 <0.001 
HDL cholesterol, mmol/L 1.34±0.31 1.29±0.32 1.24±0.30 1.19±0.29 <0.001 




1.31 [0.96-1.76] <0.001 
eGFRcrea-cysC, ml/min/1.73m
2














Data are numbers (percentages), means (SD) or medians [interquartile range (IQR)]. P-values were 
calculated by linear regression analysis or χ2 analysis. Triglycerides and UAE were logarithmically 
transformed for analysis. Data with regard to smoking and alcohol consumption were missing in 
65(1.2%) and 49 (0.9%) of the subjects, respectively. Abbreviations: BMI: Abbreviations: BMI, body mass 
index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFRcrea-cysC, estimated glomerular 
filtration rate based on creatinine-cystatin C equation; HDL, high density lipoproteins; hsCRP, high 
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sensitivity C-reactive protein; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; UAE, urinary 
albumin excretion. 
 
Mean levels of GlycA and median levels of hsCRP of the subjects were 352.3±62.0 µmol/L and 
1.36 [0.62-3.08] mg/L, respectively. In the whole group as well as in men and women separately 
there was a strong positive correlation between GlycA and hsCRP (whole group: r=0.67 P<0.001; 
men: r=0.65, P<0.001; women r=0.68, P<0.001). Both GlycA and hsCRP were higher in women than in 
men (357.1±61.4 µmol/L vs.347.0±62.3 µmol/L, P<0.001 and 1.41 [0.63-3.25] mg/L vs. 1.31 [0.62-
2.84] mg/L, P=0.04, respectively). 
At the end of a median follow-up of 8.5 [IQR, 7.9-9.0] years, 348 subjects had deceased, of which 
74 (21.3%) from CVD, 168 (48.3%) from malignancy and 106 (30.5%) from other causes. Life 
expectancy was compared in the upper quartiles of GlycA and hsCRP vs. the lower three quartiles 
combined. At start of the study, subjects in the highest quartile of GlycA were older (Table 1, 
P<0.001). The same was true for subjects in the highest quartile of hsCRP compared to the lowest 
three quartiles combined (Table 2, P<0.001). Life expectancy at the end of follow up was lower in the 
highest quartile vs. the lower three quartiles of GlycA (P<0.001) and hsCRP (P<0.001). Fifty percent of 
the deceased subjects in the highest GlycA quartile had died 1.18 years earlier than expected; this 
was 0.78 years later for the lowest three GlycA quartiles combined. Of the highest hsCRP quartile 
50% had deceased 0.48 years earlier than expected; for the lower three hsCRP quartiles combined 




Figure 2 Kaplan-Meier estimates of overall survival. The survival times were adjusted for sex, age and 
birth cohort. The time base represents the minus life expectancy in years. The lines show the distribution 
of the life expectancy at death (n=348). The green lines show the life expectancy of patients in the 
highest quartiles of A. GlycA, B. hsCRP (“dead 1”). The purple lines show the life expectancy of subjects in 
the lower three quartiles combined of A. GlycA and B. hsCRP (“dead 2”). Life expectancy at the end of 




Analyses in men (249 deceased subjects) and women (99 deceased subjects) separately showed 
that life expectancy was significantly different in both men and women in the highest quartile vs. 
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those in the lower quartiles of GlycA (P<0.001 and P=0.02, respectively). For hsCRP, men in the 
highest quartile vs. the lower three quartiles had lower life expectancy (P<0.001). However, no 
difference in life expectancy was found when we compared women in the highest quartile vs. 
women in the lowest three quartiles of hsCRP (P=0.67).  
 
4 Discussion 
This prospective study comprising 5,526 PREVEND study participants demonstrates that higher levels of 
plasma GlycA and hsCRP are associated with reduced life expectancy. Furthermore, when the analyses 
were carried out for men and women separately, men as well as women in the highest GlycA quartile 
had lower life expectancy compared to the lowest three quartiles combined. However, for hsCRP, the 
association remained only significant in men.  
 Despite the fact that GlycA and hsCRP are both markers of low-grade systemic inflammation, 
there are also some noteworthy differences. First, while GlycA is a composite biomarker that integrates 
both the increased protein levels and enhanced glycosylation states of the most abundant circulating 
acute phase proteins, hsCRP is a single biomarker of low-grade systemic inflammation. Second, as a 
result of the foregoing, GlycA has lower intra-individual variability compared to hsCRP and provides a 
less variable measure of inflammation [2]. Third, hsCRP is an early acute phase protein while the proteins 
that give rise to the GlycA signal rise later in the acute phase response [22]. Notably, hsCRP circulates at 
lower concentrations and contributes negligibly to the measured GlycA signal itself [2].  
 Although this is the first study that investigated the association between GlycA and life 
expectancy, previous studies have already revealed an association between GlycA and mortality. GlycA 
was significantly associated with all-cause, CVD, colorectal and lung cancer mortality in 27,524 initially 
healthy subjects of the Women’s Health study (WHS) [15]. Notably, participants with a history of cancer 
were not excluded in that report. In addition, the all-cause mortality associations were replicated in an 
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independent cohort of 12,527 subjects of the JUPITER study [15]. The WHS showed an association 
between GlycA and colorectal cancer (CRC) incidence and mortality. The CRC results were replicated in 
6,784 men and women from the MESA study [14]. Numerous reports have shown an association 
between hsCRP and mortality in initially healthy subjects. An overview article of 13 prospective cohort 
studies of in total nearly 63,000 men and women has shown that elevated hsCRP levels are predictive of 
near-term and long-term mortality [23]. Additionally, several studies also found an association between 
elevated hsCRP levels and cardiovascular mortality [24-31].  
Remarkably, in the current study hsCRP was only associated with reduced life expectancy in 
men. Another study in elderly men and women examined whether interleukin-6 (IL-6) and hsCRP were 
associated with relative survival time and age at death (adult lifespan) [32]. Higher levels of both markers 
predicted reduced survival time and shorter life span among older men. For women, increased IL-6 levels 
were associated with lower survival time and shorter lifespan but only in those who were not using 
estrogens at the time of measurement. Interestingly, in that study hsCRP was again only associated with 
reduced survival time and lifespan in men but not in women [32]. Although there is no certain 
explanation for the discrepant results for men and women in our study, it reinforces the idea that GlycA 
and hsCRP likely capture different aspects of the inflammatory response. Furthermore, due to the low 
number of deceased females in the highest hsCRP quartile it seems plausible that we did not have 
enough power to find an association.  
Several other methodological considerations need to be discussed. Strengths of this study 
include the prospective design and considerable follow-up period. The method that we use to examine 
life expectancy has been demonstrated to give useful information with respect to other disease 
conditions such as thyroid cancer, and effects of thyroid function status [16,17]. 
We consider it a strength that it allows to compare survival rates with individuals in the general 
Dutch population with the same sex and year of birth, enabling to reduce the influences of other risk 
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factors due to age [17]. This study also has certain limitations. First, the cohort predominantly consists of 
Caucasian individuals. Therefore, our results may not be generalizable to other population. Second, due 
to the limited number of deaths it was not feasible to conduct cause specific life expectancy analyses 
with sufficient precision.   
In conclusion, this large population based cohort study of men and women demonstrates that 
higher levels of GlycA and hsCRP were associated with reduced life expectancy. In addition, when the 
analyses were performed for men and women separately, both men and women in the highest quartiles 
of GlycA had a lower life expectancy. However, for hsCRP, only men in the highest quartile vs. the lower 
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